Article Menu
- Academic Editor
- Recommended Articles
- Related Info Link
-
More by Authors Links
- on DOAJ
- Efil, S. Can
- Kus, F.
- Koylu, B.
- Durukan, B. Mert
- Bayram, S.
- Guzel, H. Goksel
- Ozturk, B.
- Muglu, H.
- Bilici, A.
- Kose, F.
- Alan, O.
- Karapelit Agitoglu, E.
- Guner, G.
- Besen, A. Ayberk
- Helvaci, K.
- Araz, M.
- Kacan, T.
- Arslan, C.
- Unal, A.
- Eniseler, E. Bihter
- Biter, S.
- Ekinci, F.
- Aslan, F.
- Unek, I. Tugba
- Tas, S.
- Acar, O.
- Ates, O.
- Sakalar, T.
- Akbas, S.
- Karakas, H.
- Akinci, M. Bulent
- Yalcin, B.
- Yalcin, S.
- Sendur, M. Ali Nahit
- on Google Scholar
- Efil, S. Can
- Kus, F.
- Koylu, B.
- Durukan, B. Mert
- Bayram, S.
- Guzel, H. Goksel
- Ozturk, B.
- Muglu, H.
- Bilici, A.
- Kose, F.
- Alan, O.
- Karapelit Agitoglu, E.
- Guner, G.
- Besen, A. Ayberk
- Helvaci, K.
- Araz, M.
- Kacan, T.
- Arslan, C.
- Unal, A.
- Eniseler, E. Bihter
- Biter, S.
- Ekinci, F.
- Aslan, F.
- Unek, I. Tugba
- Tas, S.
- Acar, O.
- Ates, O.
- Sakalar, T.
- Akbas, S.
- Karakas, H.
- Akinci, M. Bulent
- Yalcin, B.
- Yalcin, S.
- Sendur, M. Ali Nahit
- on PubMed
- Efil, S. Can
- Kus, F.
- Koylu, B.
- Durukan, B. Mert
- Bayram, S.
- Guzel, H. Goksel
- Ozturk, B.
- Muglu, H.
- Bilici, A.
- Kose, F.
- Alan, O.
- Karapelit Agitoglu, E.
- Guner, G.
- Besen, A. Ayberk
- Helvaci, K.
- Araz, M.
- Kacan, T.
- Arslan, C.
- Unal, A.
- Eniseler, E. Bihter
- Biter, S.
- Ekinci, F.
- Aslan, F.
- Unek, I. Tugba
- Tas, S.
- Acar, O.
- Ates, O.
- Sakalar, T.
- Akbas, S.
- Karakas, H.
- Akinci, M. Bulent
- Yalcin, B.
- Yalcin, S.
- Sendur, M. Ali Nahit
Need Help?
Order Article Reprints
Journal: Cancers, 2026
Volume: 18
Number: 101
101
Article:
Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study
Authors:
by
Safa Can Efil, Fatih Kus, Bahadir Koylu, Bekir Mert Durukan, Selami Bayram, Halil Goksel Guzel, Banu Ozturk, Harun Muglu, Ahmet Bilici, Fatih Kose, Ozkan Alan, Eda Karapelit Agitoglu, Gurkan Guner, Ali Ayberk Besen, Kaan Helvaci, Murat Araz, Turgut Kacan, Cagatay Arslan, Ahmet Unal, Emine Bihter Eniseler, Sedat Biter, Ferhat Ekinci, Ferit Aslan, Ilkay Tugba Unek, Semra Tas, Omer Acar, Ozturk Ates, Teoman Sakalar, Sinem Akbas, Hilal Karakas, Muhammed Bulent Akinci, Bulent Yalcin, Suayip Yalcin and Mehmet Ali Nahit Senduradd
Show full author list
remove
Hide full author list
Link:
https://www.mdpi.com/2072-6694/18/1/101
MDPI offers high quality article reprints with convenient shipping to destinations worldwide. Each reprint features a 270 gsm bright white cover
and 105 gsm premium white paper, bound with two stitches for durability and printed in full color. The cover design is customized to your article
and designed to be complimentary to the journal.
Cite
Efil, S.C.; Kus, F.; Koylu, B.; Durukan, B.M.; Bayram, S.; Guzel, H.G.; Ozturk, B.; Muglu, H.; Bilici, A.; Kose, F.; et al. Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study. Cancers 2026, 18, 101. https://doi.org/10.3390/cancers18010101
Efil SC, Kus F, Koylu B, Durukan BM, Bayram S, Guzel HG, Ozturk B, Muglu H, Bilici A, Kose F, et al. Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study. Cancers. 2026; 18(1):101. https://doi.org/10.3390/cancers18010101
Chicago/Turabian StyleEfil, Safa Can, Fatih Kus, Bahadir Koylu, Bekir Mert Durukan, Selami Bayram, Halil Goksel Guzel, Banu Ozturk, Harun Muglu, Ahmet Bilici, Fatih Kose, and et al. 2026. "Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study" Cancers 18, no. 1: 101. https://doi.org/10.3390/cancers18010101
APA StyleEfil, S. C., Kus, F., Koylu, B., Durukan, B. M., Bayram, S., Guzel, H. G., Ozturk, B., Muglu, H., Bilici, A., Kose, F., Alan, O., Karapelit Agitoglu, E., Guner, G., Besen, A. A., Helvaci, K., Araz, M., Kacan, T., Arslan, C., Unal, A., ... Sendur, M. A. N. (2026). Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study. Cancers, 18(1), 101. https://doi.org/10.3390/cancers18010101
